CVRx (NASDAQ:CVRX) Releases Earnings Results, Misses Estimates By $0.05 EPS

Key Points

• CVRx reported a quarterly earnings per share (EPS) of **($0.57)**, missing analysts' estimates of **($0.52)** by **$0.05** and experiencing a **negative net margin** of **97.49%**.
• Stock performance saw a slight decline, trading at **$7.55**, with a market capitalization of **$196.83 million** and an average price target of **$14.50**, indicating a **"Moderate Buy"** rating from analysts.
• Insider activity included Director Kirk G. Nielsen acquiring **10,966 shares** at an average price of **$5.45**, representing a **0.58%** ownership increase, while insiders collectively purchased **78,666 shares** valued over **$411,031** in the last quarter.

CVRx (NASDAQ:CVRX - Get Free Report) announced its quarterly earnings results on Monday. The company reported ($0.57) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.52) by ($0.05), Zacks reports. The firm had revenue of $13.59 million for the quarter, compared to analyst estimates of $13.22 million. CVRx had a negative return on equity of 79.31% and a negative net margin of 95.61%. CVRx updated its FY 2025 guidance to EPS and its Q3 2025 guidance to EPS.

CVRx Stock Up 6.0%

Shares of CVRX traded up $0.42 during midday trading on Friday, reaching $7.36. The stock had a trading volume of 90,722 shares, compared to its average volume of 327,116. CVRx has a 1-year low of $4.30 and a 1-year high of $18.55. The company's fifty day simple moving average is $6.89 and its two-hundred day simple moving average is $9.42. The company has a market cap of $191.77 million, a price-to-earnings ratio of -3.50 and a beta of 1.27. The company has a debt-to-equity ratio of 0.85, a current ratio of 11.99 and a quick ratio of 13.45.

Insider Buying and Selling

In related news, Director Kirk G. Nielsen purchased 10,966 shares of the business's stock in a transaction that occurred on Thursday, May 15th. The shares were purchased at an average cost of $5.45 per share, for a total transaction of $59,764.70. Following the purchase, the director directly owned 1,910,134 shares of the company's stock, valued at $10,410,230.30. The trade was a 0.58% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In the last quarter, insiders have acquired 78,666 shares of company stock worth $411,031. 13.90% of the stock is owned by company insiders.

Institutional Trading of CVRx

A hedge fund recently raised its stake in CVRx stock. Geode Capital Management LLC boosted its holdings in shares of CVRx, Inc. (NASDAQ:CVRX - Free Report) by 6.4% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 382,437 shares of the company's stock after acquiring an additional 23,079 shares during the period. Geode Capital Management LLC owned about 1.47% of CVRx worth $2,249,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 75.27% of the company's stock.

Wall Street Analysts Forecast Growth

A number of analysts have recently issued reports on CVRX shares. William Blair upgraded shares of CVRx to a "strong-buy" rating in a report on Monday, July 7th. JPMorgan Chase & Co. reaffirmed an "underweight" rating and set a $7.00 price objective (down previously from $15.00) on shares of CVRx in a research report on Friday, May 9th. Cantor Fitzgerald reaffirmed an "overweight" rating and set a $11.00 price objective on shares of CVRx in a research report on Tuesday. Finally, Piper Sandler lowered their price objective on shares of CVRx from $20.00 to $12.00 and set an "overweight" rating for the company in a research report on Friday, May 9th. One equities research analyst has rated the stock with a sell rating, five have issued a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average price target of $14.00.

About CVRx

CVRx, Inc, a commercial-stage medical device company, focuses on developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases. The company offers Barostim, a neuromodulation device indicated to improve symptoms for patients with heart failure with reduced ejection fraction or systolic heart failure.